AU2001238584A1 - Methods of structure-based drug design using ms/nmr - Google Patents

Methods of structure-based drug design using ms/nmr

Info

Publication number
AU2001238584A1
AU2001238584A1 AU2001238584A AU3858401A AU2001238584A1 AU 2001238584 A1 AU2001238584 A1 AU 2001238584A1 AU 2001238584 A AU2001238584 A AU 2001238584A AU 3858401 A AU3858401 A AU 3858401A AU 2001238584 A1 AU2001238584 A1 AU 2001238584A1
Authority
AU
Australia
Prior art keywords
nmr
methods
drug design
based drug
design
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001238584A
Inventor
Dominick Mobilio
Franklin Joseph Moy
Robert Powers
Marshall Mayer Siegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of AU2001238584A1 publication Critical patent/AU2001238584A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001238584A 2000-02-25 2001-02-21 Methods of structure-based drug design using ms/nmr Abandoned AU2001238584A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51380600A 2000-02-25 2000-02-25
US09513806 2000-02-25
PCT/US2001/005495 WO2001062688A2 (en) 2000-02-25 2001-02-21 Methods of structure-based drug design using ms/nmr

Publications (1)

Publication Number Publication Date
AU2001238584A1 true AU2001238584A1 (en) 2001-09-03

Family

ID=24044740

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001238584A Abandoned AU2001238584A1 (en) 2000-02-25 2001-02-21 Methods of structure-based drug design using ms/nmr

Country Status (9)

Country Link
EP (1) EP1259469A2 (en)
JP (1) JP2003524167A (en)
CN (1) CN1411554A (en)
AR (1) AR027955A1 (en)
AU (1) AU2001238584A1 (en)
BR (1) BR0108606A (en)
CA (1) CA2401014A1 (en)
MX (1) MXPA02008253A (en)
WO (1) WO2001062688A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002364783A1 (en) * 2001-11-21 2003-06-10 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in general metabolism

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891742A (en) * 1995-01-19 1999-04-06 Chiron Corporation Affinity selection of ligands by mass spectroscopy
US5698401A (en) * 1995-11-14 1997-12-16 Abbott Laboratories Use of nuclear magnetic resonance to identify ligands to target biomolecules
DK0870197T4 (en) * 1995-11-14 2007-02-26 Abbott Lab Use of nuclear magnetic resonance for the design of ligands targeting biomolecules
DE69727466T2 (en) * 1996-04-08 2004-12-16 Glaxo Group Ltd., Greenford MASS-BASED CODING AND QUALITATIVE ANALYSIS OF COMBINATIONAL LIBRARIES
JP3788909B2 (en) * 1999-02-12 2006-06-21 セテク コーポレイション A high-throughput size exclusion method for screening complex physiological materials for affinity ligands

Also Published As

Publication number Publication date
BR0108606A (en) 2003-01-07
AR027955A1 (en) 2003-04-16
MXPA02008253A (en) 2002-11-29
CN1411554A (en) 2003-04-16
CA2401014A1 (en) 2001-08-30
WO2001062688A2 (en) 2001-08-30
JP2003524167A (en) 2003-08-12
EP1259469A2 (en) 2002-11-27
WO2001062688A3 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
HK1208446A1 (en) Derivatives of uk-2a uk-2a
AU2001235691A1 (en) Use of paullone derivatives for making medicines
AU3867400A (en) Methods of using bioelastomers
TWI318201B (en) Novel succinate salt of o-desmethyl-venlafaxine
AU2001291859A1 (en) Use of copolycarbonates
AU2001269529A1 (en) Medicine comprising dicyanopyridine derivative
AU2557500A (en) Methods of making compounds
AU2002224808A1 (en) Use of thienopyrimidines
AU2001233208A1 (en) Human sulfatases
IL135466A0 (en) Enzymatic modification of sterols
AU3775600A (en) Customisation of jewellery
AU2001271841A1 (en) Methods for identifying combinations of drugs
AU2002239664A1 (en) Method for drug development using individual patient response
AU2002214868A1 (en) Therapeutic oligonucleotides of reduced toxicity
AU2001238584A1 (en) Methods of structure-based drug design using ms/nmr
AU2001258659A1 (en) Improved methods of transfection
AU2001288238A1 (en) Methods of modulating activity of dxr
AU2001264900A1 (en) Pharmaceutical use of fibulin-1
AU2001272490A1 (en) Use of galiella lactone
AU2001264375A1 (en) Novel photosensitizers of 9-hydroxypheophorbide-a derivatives used for photocynamic therapy
AU2001292001A1 (en) Pharmaceutical oxan preparation
AU2001297710A1 (en) Integrated drug development techniques
AU2001249776A1 (en) Method of polycarbonate preparation
AU2001258330A1 (en) New uses of imidazolylmethyl-pyridines
AU2001292897A1 (en) Novel therapy